{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T08:27:03Z","timestamp":1769588823151,"version":"3.49.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[1994,1,1]],"date-time":"1994-01-01T00:00:00Z","timestamp":757382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1994]]},"DOI":"10.1007\/bf00684875","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T07:29:03Z","timestamp":1101713343000},"page":"S118-S126","source":"Crossref","is-referenced-by-count":57,"title":["Etoposide: current status and future perspectives in the management of malignant neoplasms"],"prefix":"10.1007","volume":"34","author":[{"given":"Chandra P.","family":"Belani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Austin","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Aisner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJM198503143121106","volume":"312","author":"PJ O'Dwyer","year":"1985","unstructured":"O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al (1985) Etoposide (VP-16-213): current status of an active anticancer drug. N Engl J Med 312:692?700","journal-title":"N Engl J Med"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJM198706043162302","volume":"316","author":"SD Williams","year":"1987","unstructured":"Williams SD, Birch R, Einhorn LH, et al (1987) Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435?1441","journal-title":"N Engl J Med"},{"key":"CR3","first-page":"268","volume":"10","author":"P Clark","year":"1991","unstructured":"Clark P, Cottier B, Joel S, et al (1991) Two prolonged schedules of single agent oral etoposide of differing duration and dose in patients with untreated small cell lung cancer (SCLC) (abstract 931). Proc Am Soc Clin Oncol 10:268","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/1097-0142(19910101)67:1+<231::AID-CNCR2820671305>3.0.CO;2-E","volume":"67","author":"DH Johnson","year":"1991","unstructured":"Johnson DH, Hainsworth JD, Hande KR, et al (1991) Current status of etoposide in the management of small cell lung cancer. Cancer 67:231?233","journal-title":"Cancer"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JCO.1992.10.2.292","volume":"10","author":"TM Waits","year":"1992","unstructured":"Waits TM, Johnson DH, Hainsworth JD, et al (1992) Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 10:292?296","journal-title":"J Clin Oncol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ajh.2830050305","volume":"5","author":"RA Bender","year":"1978","unstructured":"Bender RA, Anderson T, Fisher RI, et al (1978) Activity of epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin's lymphoma. Am J Hematol 5: 203?209","journal-title":"Am J Hematol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00254543","volume":"7","author":"RE Taylor","year":"1982","unstructured":"Taylor RE, McElwain TJ, Barrett A, et al (1982) Etoposide as a single agent in relapsed advanced lymphoma. A phase II study. Cancer Chemother Pharmacol 7:175?177","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.1984.2.10.1115","volume":"2","author":"LJ Laubenstein","year":"1984","unstructured":"Laubenstein LJ, Krigel RL, Odejnyk CM, et al (1984) Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 2:115?130","journal-title":"J Clin Oncol"},{"key":"CR9","first-page":"101","volume":"3","author":"ME Horowitz","year":"1989","unstructured":"Horowitz ME (1989) Ewing's sarcoma: current status of diagnosis and treatment. Oncology 3:101?106","journal-title":"Oncology"},{"key":"CR10","first-page":"525","volume":"71","author":"M Carli","year":"1987","unstructured":"Carli M, Perilongo G, diMontezemolo LC, et al (1987) Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group. Cancer Treat Rep 71:525?527","journal-title":"Cancer Treat Rep"},{"key":"CR11","first-page":"96","volume":"1","author":"DP Kelsen","year":"1982","unstructured":"Kelsen DP, Magill G, Cheng E, et al (1982) Phase II trial of etoposide in the treatment of upper gastrointestinal malignancies (abstract). Proc Am Soc Clin Oncol 1:96","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR12","first-page":"A257","volume":"7","author":"H Kuhrie","year":"1988","unstructured":"Kuhrie H, Meerpohl HG, Lenaz L, et al (1988) Etoposide in cisplatin-refractory ovarian cancer. Proc Am Soc Clin Oncol 7:A257","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1989.7.9.1333","volume":"7","author":"ML Slevin","year":"1989","unstructured":"Slevin ML, Clark PI, Joel SP, et al (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7:1333?1340","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"CR14","first-page":"49","volume":"17","author":"DN Carney","year":"1990","unstructured":"Carney DN, Grogan L, Smit EF, et al (1990) Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 17 [Suppl 2]:49?53","journal-title":"Semin Oncol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1200\/JCO.1990.8.10.1613","volume":"8","author":"DH Johnson","year":"1990","unstructured":"Johnson DH, Greco FA, Strupp J, et al (1990) Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8:1613?1617","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"CR16","first-page":"48","volume":"12","author":"RD Smyth","year":"1985","unstructured":"Smyth RD, Pfeffer M, Scalzo A, et al (1985) Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 12 [Suppl 2]: 48?51","journal-title":"Semin Oncol"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/thx.44.8.631","volume":"44","author":"EF Smit","year":"1989","unstructured":"Smit EF, Carney DN, Harford P, et al (1989) A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44:631?633","journal-title":"Thorax"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/1097-0142(19910101)67:1+<303::AID-CNCR2820671316>3.0.CO;2-4","volume":"67","author":"F Greco","year":"1991","unstructured":"Greco F (1991) Chronic oral etoposide. Cancer 67:303?309","journal-title":"Cancer"},{"key":"CR19","first-page":"949","volume":"60","author":"RT Eagan","year":"1976","unstructured":"Eagan RT, Carr DT, Fryak S, et al (1976) VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer. Cancer Treat Rep 60:949?951","journal-title":"Cancer Treat Rep"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/1097-0142(197805)41:5<1710::AID-CNCR2820410509>3.0.CO;2-M","volume":"141","author":"RD Tucker","year":"1978","unstructured":"Tucker RD, Ferguson A, Van Wyk C, et al (1978) Chemotherapy of small cell carcinoma of the lung with VP-16-213. Cancer 141:1710?1714","journal-title":"Cancer"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/1097-0142(19871215)60:12<2882::AID-CNCR2820601205>3.0.CO;2-A","volume":"60","author":"Y Matsui","year":"1987","unstructured":"Matsui Y, Oshima S, Kado M, et al (1987) Phase II study of oral VP-16-213 in small cell lung cancer. Cancer 60:2882?2885","journal-title":"Cancer"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/1097-0142(197708)40:2<633::AID-CNCR2820400207>3.0.CO;2-O","volume":"40","author":"M Hansen","year":"1977","unstructured":"Hansen M, Hirsch F, Dombernowsky P, et al (1977) Treatment of small cell anaplastic carcinoma of the lung with oral solution of VP-16-213 (NSC 141540, 4?-demethylepipodophyllotoxin 9-4-(4,6-O-ethylidene-?-d-glycopryanoside). Cancer 40:633?637","journal-title":"Cancer"},{"key":"CR23","first-page":"473","volume":"62","author":"F Cavilli","year":"1978","unstructured":"Cavilli F, Sonntag RW, Jungi F, et al (1978) VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 62:473?475","journal-title":"Cancer Treat Rep"},{"key":"CR24","first-page":"115","volume":"11","author":"FA Greco","year":"1992","unstructured":"Greco FA, Garrow GC, Johnson DH, et al (1992) Prolonged continuous infusion of low-dose etoposide in responsive neoplasm: preliminary phase I\/II results. Proc Am Soc Clin Oncol 11:115","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR25","first-page":"168","volume":"6","author":"LH Einhorn","year":"1987","unstructured":"Einhorn LH, Greco A, Wampler G, et al (1987) Cytoxan, adriamycin, etoposide versus cytoxan, adriamycin and vincristine in the treatment of small cell lung cancer. Proc Am Soc Clin Oncol 6:168","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.7326\/0003-4819-107-4-451","volume":"107","author":"WK Evans","year":"1987","unstructured":"Evans WK, Feld R, Murray N, et al (1987) Superiority of alternating non-cross resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 107:451?458","journal-title":"Ann Intern Med"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0002-9343(85)90308-0","volume":"79","author":"RB Natalir","year":"1985","unstructured":"Natalir RB, Shank B, Hilaris BS, et al (1985) Combination cyclophosphamide, Adriamycin and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer. Am J Med 79:303?308","journal-title":"Am J Med"},{"key":"CR28","first-page":"214","volume":"3","author":"RL Woods","year":"1984","unstructured":"Woods RL, Levi JA (1984) Chemotherapy for small cell lung cancer (SCLC2w): a randomized study of maintenance therapy with cyclophosphamide, Adriamycin and vincristine (CAV) after remission induction therapy with cisplatinum (CIS-DDP), VP-16-213 and radiotherapy. Proc Am Soc Clin Oncol 3:214","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 3","key":"CR29","first-page":"54","volume":"13","author":"J Aisner","year":"1986","unstructured":"Aisner J, Whitacre MY, Abrams J, et al (1986) Adriamycin, cytoxan, etoposide (ACE) and platinum, adriamycin, cytoxan, etoposide (PACE) for small cell carcinoma of the lung. Semin Oncol 13:54?62 (suppl 3)","journal-title":"Semin Oncol"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/BF00684843","volume":"29","author":"J Aisner","year":"1992","unstructured":"Aisner J, Whitacre MY, Budman DR, et al (1992) Cisplatin, doxorubicin, cyclosphosphamide and etoposide combination chemotherapy for small-cell lung cancer. Cancer Chemother Pharmacol 29:435?438","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/1097-0142(19910101)67:1+<250::AID-CNCR2820671307>3.0.CO;2-9","volume":"67","author":"JC Ruckdeschel","year":"1991","unstructured":"Ruckdeschel JC (1991) Etoposide in the management of non-small cell lung cancer. Cancer 67:250?253","journal-title":"Cancer"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00684958","volume":"28","author":"N Niederle","year":"1991","unstructured":"Niederle N, Ostermann J, Achterrath W, et al (1991) Etoposide in patients with previously untreated non-small cell lung cancer: a phase I study. Cancer Chemother Pharmacol 28:59?62","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/1097-0142(19900701)66:1<130::AID-CNCR2820660123>3.0.CO;2-P","volume":"66","author":"R Rosso","year":"1991","unstructured":"Rosso R, Salvati F, Ardizzoni A, et al (1991) Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force. Cancer 66:130?134","journal-title":"Cancer"},{"key":"CR34","first-page":"238","volume":"9","author":"S Saxman","year":"1990","unstructured":"Saxman S, Logie K, Stephens D, et al (1990) Phase II trial of daily oral etoposide in patients with surgically unresectable non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 9:238","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl","key":"CR35","first-page":"102","volume":"7","author":"U Gatzcincier","year":"1991","unstructured":"Gatzcincier U, Neuhauss R, Heckmayr M (1991) Single agent oral etoposide in advanced NSCLC (chronic daily) and in elderly patients with SCLC (abstract) Lung Cancer 7 [Suppl]: 102","journal-title":"Lung Cancer"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1200\/JCO.1993.11.6.1179","volume":"11","author":"AA Miller","year":"1993","unstructured":"Miller AA, Tolley EA, Niell HB, Griffin JP, Mauer AM (1993) Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 11:1179?1188","journal-title":"J Clin Oncol"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.1993.11.8.1598","volume":"11","author":"SM Grunberg","year":"1993","unstructured":"Grunberg SM, Crowley JJ, Livingston R, et al (1993) Treatment of stage IV non-small cell lung cancer (NSCLC) with long term administration of oral otoposide (E) and oral cyclophosphamide (C). A Southwest Oncology Group study. J Clin Oncol 11: 1598?1601","journal-title":"J Clin Oncol"},{"key":"CR38","first-page":"257","volume":"10","author":"J Walls","year":"1991","unstructured":"Walls J, Devore R, Hainsworth JD, et al (1991) Carboplatin (CBDCA) plus prolonged administration of oral etoposide (E) in the treatment of non-small cell lung cancer (NSCLC): a phase I\/II trial (abstract). Proc Am Soc Clin Oncol 10:257","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(77)90088-5","volume":"II","author":"E Newlands","year":"1977","unstructured":"Newlands E, Bagshawe K (1977) Epipodophyllotoxin derivative (VP16-213) in malignant teratomas and choriocarcinomas (letter). Lancet II:87","journal-title":"Lancet"},{"key":"CR40","first-page":"233","volume-title":"Etoposide (VP-16). Current status and new developments","author":"JD Hainsworth","year":"1984","unstructured":"Hainsworth JD, Greco FA, Williams SD, et al (1984) VP-16-213 in the treatment of refractory germinal neoplasms. In: Issel BF, Muggia FM, Carter SK (eds) Etoposide (VP-16). Current status and new developments, Academic Press (Harcourt Brace Iovanovich, Publishers) London, pp 233?243"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/1097-0142(19801115)46:10<2154::AID-CNCR2820461008>3.0.CO;2-3","volume":"46","author":"S Williams","year":"1980","unstructured":"Williams S, Einhorn L, Greco F, et al (1980) VP-16-213 salvage therapy for refractory germinals neoplasms. Cancer 46:2154?2158","journal-title":"Cancer"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/JCO.1986.4.3.400","volume":"4","author":"R Birch","year":"1986","unstructured":"Birch R, Williams S, Cone A, et al (1986) Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400?407","journal-title":"J Clin Oncol"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.1989.7.3.387","volume":"7","author":"LH Einhorn","year":"1989","unstructured":"Einhorn LH, Williams SD, Loehrer PJ, et al (1989) Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors. A Southwestern Cancer Study Group protocol. J Clin Oncol 7:387?391","journal-title":"J Clin Oncol"},{"key":"CR44","first-page":"169","volume":"10","author":"PJ Loehrer","year":"1991","unstructured":"Loehrer PJ, Elson P, Johnson DH, et al (1991) A randomized trial of cisplatin plus etoposide with or without bleomycin in favorable prognosis disseminated germ cell tumors (abstract) Proc Am Soc Clin Oncol 10:169","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JCO.1991.9.7.1163","volume":"9","author":"C Nichols","year":"1991","unstructured":"Nichols C, Williams S, Loehrer P, et al (1991) Randomized study of cisplatin dose intensity in advanced germ cell tumors: a Southwestern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163?1172","journal-title":"J Clin Oncol"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1200\/JCO.1986.4.1.28","volume":"4","author":"B Wheeler","year":"1986","unstructured":"Wheeler B, Loehrer P, Wiliams S, et al (1986) Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4:28?34","journal-title":"J Clin Oncol"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/0003-4819-109-7-540","volume":"109","author":"PJ Loehrer","year":"1988","unstructured":"Loehrer PJ, Lauer R, Roth BJ, et al (1988) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109:540?546","journal-title":"Ann Intern Med"},{"key":"CR48","first-page":"232","volume":"12","author":"G Stoter","year":"1993","unstructured":"Stoter G, Sleijfer DT, Schornagel JH, et al (1993) BEP versus VIP in intermediate risk patients with disseminated non-seminomatous testicular cancer (NSTC). Proc Am Soc Clin Oncol 12:232","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.1989.7.7.932","volume":"7","author":"CR Nichols","year":"1989","unstructured":"Nichols CR, Tricot G, Williams SD, et al (1989) Dose-intensive chemotherapy in refractory germ cell cancer ? a phase I\/II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932?939","journal-title":"J Clin Oncol"},{"key":"CR50","unstructured":"Rosti G, Salvioni R, Pizzocaro G, et al (1990) High dose chemotherapy (HDC) with carboplatin (CBP) and VP-16 in germ cell tumors: the Italian experience. In: Dicke K, Armitage JO, Dicke-Evinger MJ (eds) Proceedings of the Fifth International Bone Marrow Transplant Symposium, Omaha, Nebraska, pp 186"},{"issue":"Suppl 13","key":"CR51","first-page":"33","volume":"19","author":"JF Bishop","year":"1992","unstructured":"Bishop JF (1992) Etoposide in the treatment of acute leukemias. Semin Oncol 19 [Suppl 13]:33?38","journal-title":"Semin Oncol"},{"key":"CR52","first-page":"995","volume":"65","author":"AT Look","year":"1981","unstructured":"Look AT, Dahl GV, Kalwinsky D, et al (1981) Effective remission induction of refractory childhood acute non-lymphocytic leukemia by VP-16-213 plus azacytidine. Cancer Treat Rep 65:995?999","journal-title":"Cancer Treat Rep"},{"key":"CR53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/mpo.2950140502","volume":"14","author":"DK Kalwinsky","year":"1986","unstructured":"Kalwinsky DK, Dahl GV, Mirro J, et al (1986) Induction failures in childhood acute nonlymphocytic leukemia: etoposide\/5-azacytidine for cases refractory to daunorubicin\/cytarabine. Med Pediatr Oncol 14:245?250","journal-title":"Med Pediatr Oncol"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/mpo.2950130414","volume":"13","author":"L Letendre","year":"1985","unstructured":"Letendre L, Hinemann V, Hoagland C, et al (1985) Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. Med Pediatr Oncol 13:232?234","journal-title":"Med Pediatr Oncol"},{"key":"CR55","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.1986.4.3.318","volume":"4","author":"L Tschopp","year":"1986","unstructured":"Tschopp L, Fliedner VE von, Saufer C, et al (1986) Efficacy and clinical cross-resistances of a new combination therapy (AMSA\/ VP16) in previously treated patients with acute non-lymphocytic leukemia. J Clin Oncol 4:318?324","journal-title":"J Clin Oncol"},{"key":"CR56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0145-2126(85)90144-4","volume":"9","author":"AM Carella","year":"1985","unstructured":"Carella AM, Santini G, Giordano D, et al (1985) Idarubicin alone or in combination with cytarabine and etoposide (3+3+5 protocol) in acute non-lymphoblastic leukemia (letter) Leuk Res 9:631","journal-title":"Leuk Res"},{"key":"CR57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.1988.6.2.213","volume":"6","author":"AD Ho","year":"1988","unstructured":"Ho AD, Lipp T, Ehiger G, et al (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia ? an active well tolerated regimen. J Clin Oncol 6:213?217","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"CR58","first-page":"121","volume":"4","author":"M Lazzarino","year":"1989","unstructured":"Lazzarino M, Morra E, Alessandrino EP, et al (1989) Treatment of relapsed or refractory acute myeloid leukemia in adults. Bone Marrow Transplant [Suppl] 4:121?123","journal-title":"Bone Marrow Transplant"},{"key":"CR59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.1986.tb01115.x","volume":"16","author":"JF Bishop","year":"1986","unstructured":"Bishop JF, Joshua DE, Lowenthal RM, et al (1986) A phase I-II study of cytosine arabinoside, daunorubicin and VP16-213 in adult patients with acute non-lymphocytic leukemia. Aust NZ J Med 16:48?51","journal-title":"Aust NZ J Med"},{"key":"CR60","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7326\/0003-4819-73-6-881","volume":"73","author":"VT DeVita","year":"1970","unstructured":"DeVita VT, Serpick AA, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:891?895","journal-title":"Ann Intern Med"},{"key":"CR61","first-page":"A941","volume":"10","author":"J Glick","year":"1991","unstructured":"Glick J, Tsiatis A, Schilsky R, et al (1991) A randomized phase III trial of MOPP\/ABVD hybrid vs. sequential MOPP-ABVD in advanced Hodgkin's disease: preliminary results of the Intergroup Trial (abstract). Proc Am Soc Clin Oncol 10:A941","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","volume":"36","author":"G Bonadonna","year":"1975","unstructured":"Bonadonna G, Zucali R, Monfardini S, et al (1975) Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboximide versus MOPP. Cancer 36:252?259","journal-title":"Cancer"},{"key":"CR63","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.1986.4.9.1295","volume":"4","author":"DL Longo","year":"1986","unstructured":"Longo DL, Young RC, Wesley M, et al (1986) Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295?1306","journal-title":"J Clin Oncol"},{"key":"CR64","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.1987.5.4.544","volume":"5","author":"KA Fox","year":"1987","unstructured":"Fox KA, Lippman SM, Cassady JR, et al (1987) Radiation therapy salvage of Hodgkin's, disease following chemotherapy. J Clin Oncol 5:544?549","journal-title":"J Clin Oncol"},{"key":"CR65","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00253064","volume":"18","author":"MA Richards","year":"1986","unstructured":"Richards MA, Waxman JH, Ganesan TS, et al (1986) EVA treatment for recurrent or unresponsive Hodgkin's disease. Cancer Chemother Pharmacol 18: 51?53","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR66","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1992.10.2.210","volume":"10","author":"DL Longo","year":"1992","unstructured":"Longo DL, Duffey PL, Young RC, et al (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10: 210?218","journal-title":"J Clin Oncol"},{"key":"CR67","first-page":"475","volume":"71","author":"A Tseng Jr","year":"1987","unstructured":"Tseng A Jr, Jacobs C, Coleman CN, et al (1987) Third line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide and methotrexate. Cancer Treat Rep 71: 475?478","journal-title":"Cancer Treat Rep"},{"key":"CR68","first-page":"1203","volume":"71","author":"MG Pfreundschuh","year":"1987","unstructured":"Pfreundschuh MG, Schoppe WD, Fuchss R, et al (1987) Lomustine, etoposide, vindesine and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine and decarbazine: a multicenter trial of the German Hodgkin's Study Group. Cancer Treat Rep 71: 1203?1207","journal-title":"Cancer Treat Rep"},{"key":"CR69","first-page":"23","volume":"13","author":"A Santoro","year":"1986","unstructured":"Santoro A, Viviani SS, Valagussa P, et al (1986) CCNU, etoposide and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 13: 23?26","journal-title":"Semin Oncol"},{"key":"CR70","first-page":"665","volume":"70","author":"F Cervantes","year":"1986","unstructured":"Cervantes F, Reverter JC, Montserrat E, et al (1986) Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide and prednimustine. Cancer Treat Rep 70: 665?667","journal-title":"Cancer Treat Rep"},{"key":"CR71","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1987.5.4.556","volume":"5","author":"FBN Hagemeister","year":"1987","unstructured":"Hagemeister FBN, Tannir N, McLaughlin P, et al (1987) MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5: 556?561","journal-title":"J Clin Oncol"},{"key":"CR72","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/blood.V73.1.340.340","volume":"73","author":"JG Gribben","year":"1989","unstructured":"Gribben JG, Linch DC, Singer CRJ, et al (1989) Successful treatment of refractory Hodgkin's disease by high dose combination chemotherapy and autologous bone marrow transplantation. Blood 73: 340","journal-title":"Blood"},{"key":"CR73","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0360-3016(89)90136-3","volume":"17","author":"J Yahalom","year":"1989","unstructured":"Yahalom J, Girlati S, Shank B, et al (1989) Total lymphoid irradiation, high dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease. Int J Radiat Oncol Biol Phys 17: 915","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR74","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-98-3-304","volume":"98","author":"RI Fisher","year":"1983","unstructured":"Fisher RI, Devita VT Jr, Hubbard SM, et al (1983) Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of Pro MACE and MOPP chemotherapy. Ann Intern Med 98: 304?309","journal-title":"Ann Intern Med"},{"key":"CR75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1991.9.1.25","volume":"9","author":"DL Longo","year":"1991","unstructured":"Longo DL, DeVita VT Jr, Duffy PL, et al (1991) Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 9: 25?38","journal-title":"J Clin Oncol"},{"key":"CR76","first-page":"95","volume":"5","author":"M Frederico","year":"1991","unstructured":"Frederico M, Moretti G, Gobbi PG, et al (1991) ProMACE-CytaBOM vs. MACOP-B in intermediate and high-grade NHL. Preliminary results of a prospective randomized trial. Leukemia 5: 95?101","journal-title":"Leukemia"},{"key":"CR77","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/annonc\/2.suppl_1.17","volume":"2","author":"SE O'Reilly","year":"1991","unstructured":"O'Reilly SE, Hoskins P, Kleins P, et al (1991) MACP-B and VACOP-B in diffuse large cell lymphomas and MOPP\/ABD in Hodgkin's disease. Ann Oncol 2: 17?23","journal-title":"Ann Oncol"},{"key":"CR78","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor E, Dahlberg S, et al (1993) Comparison of a standard regimen (CHOPE) with three intensive chemotherapy programmes for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002?1006","journal-title":"N Engl J Med"},{"key":"CR79","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/1097-0142(19910101)67:1+<292::AID-CNCR2820671314>3.0.CO;2-7","volume":"67","author":"RH Herzig","year":"1991","unstructured":"Herzig RH (1991) High-dose etoposide and marrow transplantation. Cancer 67: 292?298","journal-title":"Cancer"},{"key":"CR80","first-page":"559","volume":"4","author":"GR Spitzer","year":"1989","unstructured":"Spitzer GR, Cottler-Fox M, Torrisi J, et al (1989) Escalating doses of etoposide with a cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant 4: 559?565","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"CR81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/2.suppl_1.47","volume":"2","author":"SJ Horning","year":"1991","unstructured":"Horning SJ, Chao NJ, Negrin RS, et al (1991) The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol 2 [Suppl 1] 47?50","journal-title":"Ann Oncol"},{"key":"CR82","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.1990.8.5.784","volume":"8","author":"AS Freedman","year":"1990","unstructured":"Freedman AS, Takvorian T, Anderson KC, et al (1990) Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment related mortality in 100 patients in sensitive relapse. J Clin Oncol 8: 784?791","journal-title":"J Clin Oncol"},{"key":"CR83","first-page":"276","volume":"10","author":"WH Wilson","year":"1991","unstructured":"Wilson WH, Bryant G, Bates S, et al (1991) Infusional etoposide (E), vincristine (O) and Adriamycin (H) with cyclophosphamide (C), prednisone (P) (EPOCH) and r-verapamil (RV) in relapsed lymphoma (abstract). Proc Am Soc Clin Oncol 10: 276","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR84","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0140-6736(90)90001-L","volume":"335","author":"V Beral","year":"1990","unstructured":"Beral V, Peterman TA, Berkelman RL, et al (1990) Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335: 123","journal-title":"Lancet"},{"key":"CR85","first-page":"1","volume":"8","author":"P Shields","year":"1989","unstructured":"Shields P, Dawkins F, Holmlund J, et al (1989) Weekly low-dose multidrug chemotherapy (MDCT) plus pneumocystis prophylaxis for HIV-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 8: 1","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR86","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1989.7.9.1310","volume":"7","author":"P Preusser","year":"1989","unstructured":"Preusser P, Wilke H, Achterrath W, et al (1989) Phase II study with the combination of etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310?1317","journal-title":"J Clin Oncol"},{"key":"CR87","first-page":"103","volume":"9","author":"A Lerner","year":"1990","unstructured":"Lerner A, Steele GD, Mayer RJ (1990) Etoposide, doxorubicin, cisplatin (EAP) chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial (abstract). Proc Am Soc Clin Oncol 9: 103","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR88","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1989.7.9.1318","volume":"7","author":"H Wilke","year":"1989","unstructured":"Wilke H, Preusser P, Fink U, et al (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol 7: 1318?1326","journal-title":"J Clin Oncol"},{"key":"CR89","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.1992.10.4.541","volume":"10","author":"D Kelsen","year":"1992","unstructured":"Kelsen D, Atiq O, Saltz L, et al (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 10: 541?548","journal-title":"J Clin Oncol"},{"key":"CR90","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00216926","volume":"8","author":"H Wilke","year":"1990","unstructured":"Wilke H, Preusser P, Fink U, et al (1990) High dose folinic acid\/etoposide\/5-fluorouracil in advanced gastric cancer: a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 8: 65?70","journal-title":"Invest New Drugs"},{"key":"CR91","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1056\/NEJM198705283162207","volume":"316","author":"I Pastan","year":"1987","unstructured":"Pastan I, Gottesman MM (1987) Multi-drug resistance in human cancer. N Engl J Med 316: 1388?1393","journal-title":"N Engl J Med"},{"key":"CR92","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/81.2.116","volume":"81","author":"LJ Goldstein","year":"1989","unstructured":"Goldstein LJ, Galski H, Fojo A, et al (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116?124","journal-title":"J Natl Cancer Inst"},{"key":"CR93","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1073\/pnas.84.1.265","volume":"84","author":"A Fojo","year":"1987","unstructured":"Fojo A, Ueda K, Salmon DJ, et al (1987) Expression of a multidrug-resistant gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265?269","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR94","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bjc.1991.152","volume":"63","author":"K Nooter","year":"1991","unstructured":"Nooter K, Herweijer H (1991) Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63: 663?669","journal-title":"Br J Cancer"},{"key":"CR95","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1172\/JCI112450","volume":"77","author":"L Slater","year":"1986","unstructured":"Slater L, Sweet P, Stupecky M, et al (1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in-vitro. J Clin Invest 77: 1405?1408","journal-title":"J Clin Invest"},{"key":"CR96","first-page":"591","volume":"46","author":"M Willingham","year":"1986","unstructured":"Willingham M, Cornwell M, Cardarelli, C et al (1986) Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and sensitive KB cells: effects of verapamil and other drugs. Cancer Res 46: 591?594","journal-title":"Cancer Res"},{"key":"CR97","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/S0021-9258(18)61633-3","volume":"26","author":"M Cornwell","year":"1987","unstructured":"Cornwell M, Pastan I, Gottesman M (1987) Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 26: 2166?2170","journal-title":"J Biol Chem"},{"key":"CR98","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.1992.10.10.1635","volume":"10","author":"BL Lum","year":"1992","unstructured":"Lum BL, Kaubisch S, Yahanda AM, et al (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635?1642","journal-title":"J Clin Oncol"},{"key":"CR99","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.1992.10.10.1624","volume":"10","author":"M Yahanda","year":"1992","unstructured":"Yahanda M, Adler KM, Fisher GA, et al (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10: 1624?1634","journal-title":"J Clin Oncol"},{"key":"CR100","first-page":"137","volume":"12","author":"JR Eckhardt","year":"1993","unstructured":"Eckhardt JR, Burris HA, Rodriquez GA, Fields SM, et al (1993) A phase I study of topoisomerase I and II inhibitors topotecan (T) and etoposide (E) (abstract). Proc Am Soc Clin Oncol 12: 137","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR101","first-page":"169","volume":"2","author":"LA Doyle","year":"1990","unstructured":"Doyle LA, Hamburger AW, Goldstein LH, et al (1990) Interaction of recombinant human tumor necrosis factor (TNF) and etoposide in human lung cancer cell lines. Mol Biother 2: 169?174","journal-title":"Mol Biother"},{"key":"CR102","first-page":"6745","volume":"49","author":"LA Doyle","year":"1989","unstructured":"Doyle LA, Guangiulio D, Hussain A, et al (1989) Differentiation of human variant small cell lung cancer cell lines to a classic morphology by retinoic acid. Cancer Res 49: 6745?6751","journal-title":"Cancer Res"},{"issue":"Suppl 13","key":"CR103","first-page":"10","volume":"19","author":"DD Hoff Von","year":"1992","unstructured":"Von Hoff DD, McGill J, Davidson K, et al (1992) Preclinical leads for innovative uses of etoposide. Semin Oncol 19 [Suppl 13]: 10?13","journal-title":"Semin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00684875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00684875\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00684875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:20:09Z","timestamp":1625012409000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00684875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994]]},"references-count":103,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1994]]}},"alternative-id":["BF00684875"],"URL":"https:\/\/doi.org\/10.1007\/bf00684875","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994]]}}}